OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments

Supplementary statement for 2020 Shareholders’ Meeting (Change in location and new items)
May 8, 2020
OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA
May 29, 2020
  1. Date of occurrence of the event:26 May 2020
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office
  4. Reciprocal shareholding ratios: No applicable
  5. Cause of occurrence: OBI has entered into a non-binding memorandum of understanding with a biotech company intending to form a strategic partnership to develop novel bispecific antibodies for cancer treatments. Regarding this MOU is not allowed to disclose in accordance with the confidentiality obligation. A further announcement will be published upon the subsequent official contract executed.
  6. Countermeasures: None
  7. Any other matters that need to be specified: New drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.